Oliver Fetzer has been named the new CEO of Cerulean Pharma, a Cambridge, MA-based developer of nanoparticle-based drugs for cancer and other diseases, according to the company. Fetzer, who was previously senior vice president of corporate development and R&D at Lexington, MA-based Cubist Pharmaceuticals (NASDAQ:[[ticker:CBST]]), is taking over the chief executive post from veteran biotech executive and venture capitalist Alan Crane. Crane, who is the founding CEO of Cerulean and a venture partner at Polaris Venture Partners in Waltham, MA, has been named the biotech’s chairman of the board. Polaris is an investor in Cerulean.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
